Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1995 Aug;63(8):2906–2911. doi: 10.1128/iai.63.8.2906-2911.1995

Capsular polysaccharide-protein conjugate vaccines of carbotype 1 Vibrio vulnificus: construction, immunogenicity, and protective efficacy in a murine model.

S J Devi 1, U Hayat 1, C E Frasch 1, A S Kreger 1, J G Morris Jr 1
PMCID: PMC173395  PMID: 7622211

Abstract

Vibrio vulnificus causes septicemia and wound infections in immunocompromised humans. The capsular polysaccharide of Vibrio vulnificus (VvPS) is critical for virulence. We synthesized conjugate vaccines of carbotype 1 VvPS under conditions and in formulations suitable for human use. Purified VvPS was conjugated to tetanus toxoid (TT) or to inactivated V. vulnificus cytolysin or elastase by two different schemes. All conjugates elicited elevated anticapsular immunoglobulin G (IgG) and IgM and antiprotein IgG responses in mice compared with saline placebo. The conjugates prepared through caboxyl activation of VvPS (VvPS-TTa, VvPS-cytolysin, and VvPS-elastase) were more immunogenic than the one prepared through hydroxyl activation (VvPS-TTb). The protective efficacy of conjugated and unconjugated formulations of VvPS and that of protein carriers were evaluated in a mouse septicemia model. Eighty percent of mice actively immunized with VvPS-TTa vaccine survived challenge with carbotype 1 V. vulnificus, while VvPS-cytolysin and VvPS-elastase conjugates conferred 44 and 40% protection, respectively. Control mice immunized with VvPS, cytolysin, or elastase alone, or saline only, showed 70 to 100% mortality. VvPS-TTa vaccine is nontoxic, immunogenic, and protective in mice.

Full Text

The Full Text of this article is available as a PDF (294.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blake P. A., Merson M. H., Weaver R. E., Hollis D. G., Heublein P. C. Disease caused by a marine Vibrio. Clinical characteristics and epidemiology. N Engl J Med. 1979 Jan 4;300(1):1–5. doi: 10.1056/NEJM197901043000101. [DOI] [PubMed] [Google Scholar]
  2. Carruthers M. M., Kabat W. J. Vibrio vulnificus (lactose-positive vibrio) and Vibrio parahaemolyticus differ in their susceptibilities to human serum. Infect Immun. 1981 May;32(2):964–966. doi: 10.1128/iai.32.2.964-966.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chin K. P., Lowe M. A., Tong M. J., Koehler A. L. Vibrio vulnificus infection after raw oyster ingestion in a patient with liver disease and acquired immune deficiency syndrome-related complex. Gastroenterology. 1987 Mar;92(3):796–799. doi: 10.1016/0016-5085(87)90035-7. [DOI] [PubMed] [Google Scholar]
  4. Devi S. J., Schneerson R., Egan W., Ulrich T. J., Bryla D., Robbins J. B., Bennett J. E. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect Immun. 1991 Oct;59(10):3700–3707. doi: 10.1128/iai.59.10.3700-3707.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Farmer J. J., 3rd Vibrio ("Beneckea") vulnificus, the bacterium associated with sepsis, septicaemia, and the sea. Lancet. 1979 Oct 27;2(8148):903–903. doi: 10.1016/s0140-6736(79)92715-6. [DOI] [PubMed] [Google Scholar]
  6. Gotschlich E. C., Goldschneider I., Artenstein M. S. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med. 1969 Jun 1;129(6):1367–1384. doi: 10.1084/jem.129.6.1367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gray L. D., Kreger A. S. Detection of anti-Vibrio vulnificus cytolysin antibodies in sera from mice and a human surviving V. vulnificus disease. Infect Immun. 1986 Mar;51(3):964–965. doi: 10.1128/iai.51.3.964-965.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gray L. D., Kreger A. S. Mouse skin damage caused by cytolysin from Vibrio vulnificus and by V. vulnificus infection. J Infect Dis. 1987 Feb;155(2):236–241. doi: 10.1093/infdis/155.2.236. [DOI] [PubMed] [Google Scholar]
  9. Gray L. D., Kreger A. S. Purification and characterization of an extracellular cytolysin produced by Vibrio vulnificus. Infect Immun. 1985 Apr;48(1):62–72. doi: 10.1128/iai.48.1.62-72.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hayat U., Reddy G. P., Bush C. A., Johnson J. A., Wright A. C., Morris J. G., Jr Capsular types of Vibrio vulnificus: an analysis of strains from clinical and environmental sources. J Infect Dis. 1993 Sep;168(3):758–762. doi: 10.1093/infdis/168.3.758. [DOI] [PubMed] [Google Scholar]
  11. Hoge C. W., Watsky D., Peeler R. N., Libonati J. P., Israel E., Morris J. G., Jr Epidemiology and spectrum of Vibrio infections in a Chesapeake Bay community. J Infect Dis. 1989 Dec;160(6):985–993. doi: 10.1093/infdis/160.6.985. [DOI] [PubMed] [Google Scholar]
  12. Johnson D. E., Calia F. M., Musher D. M., Goree A. Resistance of Vibrio vulnificus to serum bactericidal and opsonizing factors: relation to virulence in suckling mice and humans. J Infect Dis. 1984 Sep;150(3):413–418. doi: 10.1093/infdis/150.3.413. [DOI] [PubMed] [Google Scholar]
  13. Johnston J. M., Becker S. F., McFarland L. M. Vibrio vulnificus. Man and the sea. JAMA. 1985 May 17;253(19):2850–2853. doi: 10.1001/jama.253.19.2850. [DOI] [PubMed] [Google Scholar]
  14. Kaper J. B., Morris J. G., Jr, Levine M. M. Cholera. Clin Microbiol Rev. 1995 Jan;8(1):48–86. doi: 10.1128/cmr.8.1.48. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Klontz K. C., Lieb S., Schreiber M., Janowski H. T., Baldy L. M., Gunn R. A. Syndromes of Vibrio vulnificus infections. Clinical and epidemiologic features in Florida cases, 1981-1987. Ann Intern Med. 1988 Aug 15;109(4):318–323. doi: 10.7326/0003-4819-109-4-318. [DOI] [PubMed] [Google Scholar]
  16. Koenig K. L., Mueller J., Rose T. Vibrio vulnificus. Hazard on the half shell. West J Med. 1991 Oct;155(4):400–403. [PMC free article] [PubMed] [Google Scholar]
  17. Kothary M. H., Kreger A. S. Production and partial characterization of an elastolytic protease of Vibrio vulnificus. Infect Immun. 1985 Nov;50(2):534–540. doi: 10.1128/iai.50.2.534-540.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kothary M. H., Kreger A. S. Purification and characterization of an elastolytic protease of Vibrio vulnificus. J Gen Microbiol. 1987 Jul;133(7):1783–1791. doi: 10.1099/00221287-133-7-1783. [DOI] [PubMed] [Google Scholar]
  19. Kreger A. S., Gray L. D., Testa J. Protection of mice against Vibrio vulnificus disease by vaccination with surface antigen preparations and anti-surface antigen antisera. Infect Immun. 1984 Sep;45(3):537–543. doi: 10.1128/iai.45.3.537-543.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Kreger A., DeChatelet L., Shirley P. Interaction of Vibrio vulnificus with human polymorphonuclear leukocytes: association of virulence with resistance to phagocytosis. J Infect Dis. 1981 Sep;144(3):244–248. doi: 10.1093/infdis/144.3.244. [DOI] [PubMed] [Google Scholar]
  21. Kreger A., Lockwood D. Detection of extracellular toxin(s) produced by Vibrio vulnificus. Infect Immun. 1981 Aug;33(2):583–590. doi: 10.1128/iai.33.2.583-590.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Lee C. J., Lock R. A., Andrew P. W., Mitchell T. J., Hansman D., Paton J. C. Protection of infant mice from challenge with Streptococcus pneumoniae type 19F by immunization with a type 19F polysaccharide--pneumolysoid conjugate. Vaccine. 1994 Aug;12(10):875–878. doi: 10.1016/0264-410x(94)90028-0. [DOI] [PubMed] [Google Scholar]
  23. Levine M. M., Nalin D. R., Craig J. P., Hoover D., Bergquist E. J., Waterman D., Holley H. P., Hornick R. B., Pierce N. P., Libonati J. P. Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity. Trans R Soc Trop Med Hyg. 1979;73(1):3–9. doi: 10.1016/0035-9203(79)90119-6. [DOI] [PubMed] [Google Scholar]
  24. Madoff L. C., Paoletti L. C., Tai J. Y., Kasper D. L. Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes. J Clin Invest. 1994 Jul;94(1):286–292. doi: 10.1172/JCI117319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Morris J. G., Jr, Black R. E. Cholera and other vibrioses in the United States. N Engl J Med. 1985 Feb 7;312(6):343–350. doi: 10.1056/NEJM198502073120604. [DOI] [PubMed] [Google Scholar]
  26. Morris J. G., Jr Vibrio vulnificus--a new monster of the deep? Ann Intern Med. 1988 Aug 15;109(4):261–263. doi: 10.7326/0003-4819-109-4-261. [DOI] [PubMed] [Google Scholar]
  27. Murphy T. V., White K. E., Pastor P., Gabriel L., Medley F., Granoff D. M., Osterholm M. T. Declining incidence of Haemophilus influenzae type b disease since introduction of vaccination. JAMA. 1993 Jan 13;269(2):246–248. [PubMed] [Google Scholar]
  28. Nishina Y., Miyoshi S., Nagase A., Shinoda S. Significant role of an exocellular protease in utilization of heme by Vibrio vulnificus. Infect Immun. 1992 May;60(5):2128–2132. doi: 10.1128/iai.60.5.2128-2132.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Park S. D., Shon H. S., Joh N. J. Vibrio vulnificus septicemia in Korea: clinical and epidemiologic findings in seventy patients. J Am Acad Dermatol. 1991 Mar;24(3):397–403. doi: 10.1016/0190-9622(91)70059-b. [DOI] [PubMed] [Google Scholar]
  30. Reddy G. P., Hayat U., Abeygunawardana C., Fox C., Wright A. C., Maneval D. R., Jr, Bush C. A., Morris J. G., Jr Purification and determination of the structure of capsular polysaccharide of Vibrio vulnificus M06-24. J Bacteriol. 1992 Apr;174(8):2620–2630. doi: 10.1128/jb.174.8.2620-2630.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Shinoda S., Kobayashi M., Yamada H., Yoshida S., Ogawa M., Mizuguchi Y. Inhibitory effect of capsular antigen of Vibrio vulnificus on bactericidal activity of human serum. Microbiol Immunol. 1987;31(5):393–401. doi: 10.1111/j.1348-0421.1987.tb03102.x. [DOI] [PubMed] [Google Scholar]
  32. Simpson L. M., White V. K., Zane S. F., Oliver J. D. Correlation between virulence and colony morphology in Vibrio vulnificus. Infect Immun. 1987 Jan;55(1):269–272. doi: 10.1128/iai.55.1.269-272.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Tacket C. O., Brenner F., Blake P. A. Clinical features and an epidemiological study of Vibrio vulnificus infections. J Infect Dis. 1984 Apr;149(4):558–561. doi: 10.1093/infdis/149.4.558. [DOI] [PubMed] [Google Scholar]
  34. Tzianabos A. O., Onderdonk A. B., Rosner B., Cisneros R. L., Kasper D. L. Structural features of polysaccharides that induce intra-abdominal abscesses. Science. 1993 Oct 15;262(5132):416–419. doi: 10.1126/science.8211161. [DOI] [PubMed] [Google Scholar]
  35. Tzianabos A. O., Onderdonk A. B., Smith R. S., Kasper D. L. Structure-function relationships for polysaccharide-induced intra-abdominal abscesses. Infect Immun. 1994 Aug;62(8):3590–3593. doi: 10.1128/iai.62.8.3590-3593.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Wright A. C., Morris J. G., Jr, Maneval D. R., Jr, Richardson K., Kaper J. B. Cloning of the cytotoxin-hemolysin gene of Vibrio vulnificus. Infect Immun. 1985 Dec;50(3):922–924. doi: 10.1128/iai.50.3.922-924.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Wright A. C., Morris J. G., Jr The extracellular cytolysin of Vibrio vulnificus: inactivation and relationship to virulence in mice. Infect Immun. 1991 Jan;59(1):192–197. doi: 10.1128/iai.59.1.192-197.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Wright A. C., Simpson L. M., Oliver J. D., Morris J. G., Jr Phenotypic evaluation of acapsular transposon mutants of Vibrio vulnificus. Infect Immun. 1990 Jun;58(6):1769–1773. doi: 10.1128/iai.58.6.1769-1773.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Yoshida S., Ogawa M., Mizuguchi Y. Relation of capsular materials and colony opacity to virulence of Vibrio vulnificus. Infect Immun. 1985 Feb;47(2):446–451. doi: 10.1128/iai.47.2.446-451.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES